UNTERNEHMENSDATEN
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
KURSVERLAUF
1T
-0,7 %
1W
-2,9 %
1M
+0,8 %
6M
-5,1 %
YTD
-4,4 %
1J
+0 %
2J
+5,5 %
5J
+36,4 %
10J
–
FRAG DIE AGENTEN ZU HRMY
Keine Anlageberatung. Für die vollständige Analyse-Übersicht: zur Analyse-Seite →
ANALYSTEN-EINSCHÄTZUNG
KURSZIEL TIEF
36,00 $
KONSENS
44,00 $
MEDIAN
46,00 $
KURSZIEL HOCH
50,00 $
0
STRONG BUY
8
BUY
3
HOLD
2
SELL
0
STRONG SELL
13
GESAMT · Buy
| DATUM | ANALYSTENHAUS | RATING | AKTION |
|---|---|---|---|
| 16.07.2026 | HC Wainwright & Co. | Buy | maintain |
| 30.06.2026 | Deutsche Bank | Hold | maintain |
| 08.05.2026 | Truist Securities | Hold | maintain |
| 25.02.2026 | B of A Securities | Underperform | maintain |
| 25.02.2026 | HC Wainwright & Co. | Buy | maintain |
| 25.02.2026 | UBS | Neutral | maintain |
| 25.02.2026 | Needham | Buy | maintain |
| 11.02.2026 | UBS | Buy → Neutral | downgrade |
KENNZAHLEN
KGV
14,19
KBV
2,27
EV/EBITDA
7,23
EIGENKAPITALRENDITE
3,6 %
NETTOMARGE
15,1 %
VERSCHULDUNG (D/E)
0,23
DIVIDENDENRENDITE
0 %
STAND
31.03.2026
FREE FLOAT & LIQUIDITÄT
STREUBESITZ
87 %
AKTIEN IM STREUBESITZ
50.375.969
Ø TAGESVOLUMEN (30T)
864.083
INVESTIERTE FONDS
| FONDS / INSTITUTION | ANTEILE | VERÄNDERUNG | STAND |
|---|---|---|---|
| CX Institutional | 259.496 | +14.809 | 30.06.2026 |
| Robeco Institutional Asset Management B.V. | 98.157 | -6.154 | 30.06.2026 |
| EXCHANGE TRADED CONCEPTS, LLC | 87.891 | +879 | 30.06.2026 |
| WEDGE CAPITAL MANAGEMENT L L P/NC | 82.530 | -6.469 | 30.06.2026 |
| CWA Asset Management Group, LLC | 61.273 | +14.672 | 30.06.2026 |
Keine Anlageberatung. Vergangene Wertentwicklung ist kein Indikator für zukünftige Ergebnisse.